Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Vertex Pharmaceuticals: Balancing Growth Prospects and Uncertainties with a Hold Rating
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
Yahoo Finance20d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...
Benzinga.com27d
Check Out What Whales Are Doing With VRTX
Anticipated earnings release is in 47 days ... Stay informed about the latest Vertex Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
Yahoo Finance21d
Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): ‘This Is Hardly Down For The Year. I Think It Can Still Go Lower’
In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ... the Personal Consumption Expenditure (PCE) data release. The PCE data was a boon for investors ...
Nasdaq26d
Vertex Pharmaceuticals price target lowered to $522 from $545 at BofA
BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $522 from $545 and keeps a Buy rating on the shares after the company reported topline Phase 2 results for suzetrigine in ...
STAT27d
Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study
Vertex Pharmaceuticals said Thursday that its closely ... The company said in a press release that it believes addressing variability among responses in placebo patients by better designing ...
Business Wire22d
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43 rd Annual J.P ...